These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014 [TBL] [Abstract][Full Text] [Related]
11. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027 [TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022 [TBL] [Abstract][Full Text] [Related]
13. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Hollander E; Baldini Rossi N; Sood E; Pallanti S Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454 [TBL] [Abstract][Full Text] [Related]
14. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652 [TBL] [Abstract][Full Text] [Related]
15. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636 [TBL] [Abstract][Full Text] [Related]
16. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study. Stryjer R; Budnik D; Ebert T; Green T; Polak L; Weizman S; Spivak B Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662 [TBL] [Abstract][Full Text] [Related]
17. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795 [TBL] [Abstract][Full Text] [Related]
18. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study. Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354 [TBL] [Abstract][Full Text] [Related]
19. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523 [TBL] [Abstract][Full Text] [Related]
20. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. Denys D; van der Wee N; van Megen HJ; Westenberg HG J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]